Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan vs Trabectedin in DD Liposarcoma
NCT04979442Phase 3Terminated
- Sponsor
- Rain Oncology Inc.
- Start
- Jul 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of milademetan in dedifferentiated liposarcoma (DDL), sponsored by Rain Oncology Inc.. Started Jul 2021; status: terminated.
02
Drugs
milademetan
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT04979442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979442.